Activity of daptomycin, ciprofloxacin, clindamycin and cotrimoxazole against coagulase-negative Staphylococcus strains with diminished susceptibility to vancomycin;Actividad de daptomicina, ciprofloxacino, clindamicina y cotrimoxazol frente a diferentes cepas de Staphylococcus coagulasa negativo con sensibilidad conservada y disminuida para vancomicina

Revista Espanola de Quimioterapia

Volumn 23, Issue 2, 2010, Pages 81-86

  Fajardo Olivares, Miguel ^a   Hidalgo Orozco, Rocío ^a   Rodríguez Gutierrez, Saray ^a   Garduno Eseverri, Eugenio ^a   Rodríguez Vidigal, Francisco Félix ^a   Robles Marcos, Manuel ^a  

^a HOSPITAL INFANTA CRISTINA   (Spain)

Author keywords

Ciprofloxacin; Clindamycin; Dptomycin; Staphylococcus; Vancomycin

Indexed keywords

AGAR; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; COAGULASE NEGATIVE STAPHYLOCOCCUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN;

CIPROFLOXACIN; CLINDAMYCIN; COAGULASE; DAPTOMYCIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; VANCOMYCIN RESISTANCE;

EID: 77956467608     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Ponticelli C. New recommendations in the treatment of Granpositive bacteraemia in dialysis patients. Nephrol Dial Transplant 2008; 23:27-32.
2. Cuevas O, Cercenado E, Goyanes MJ, Vindel A, trincado P, Boquete T. Staphylococcus spp en Espaha: situación actual y evolución de la resistencia a antimicrobianos (1986-2006). Enferm Infecc Microbiol Clin 2008, 26:269-77.
3. Wenzel RP, Edmon MB. Team based prevention of cateter related infections. N Eng J Med 2007; 355:2781-3.
4. Mensa J, Barberan J, Llenares P, Picazo JJ, Bouza E, Alvarez-Lerma F, et al. Guia de tratamiento de las infecciones producidas por Staphylococcus aureus resistentes a meticilina. Rev Esp Quimioter 2008; 21(4):234-58.
5. Archer GL. Staphylococcus epidermidis and other Coagulase Negative Staphylococci. In: Mandell, Douglas and Bennett (Eds). Principles and Practice of Infectious disease. 5th Edition. Churchill Livingstone, p 2092-100.
6. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin resistant Staphylococcus aureus sterile site infection. The importance of appropriate initial antimicrobial treatment. Crit Car Med 2006; 34:2069-74.
7. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatmen of methicillin resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46:193-200. (Pubitemid 351269157)
8. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with MRSA bacteremia treated with vancomycin. Antimicrob Agent Chemother 2008; 52:3315-20.
9. Rice DAK, Mendez-Vigo L. Daptomycin in bone and joint infectious. A review of the literature. Arch Orthop Trauma Surg 2008 DOI 10.1007/500402-008- 0772-x
10. Darley E, NcGrowan A. Antibiotic treatment of Gram-positive bone and joint infection. J Antimicrob Chemother 2004; 53:928-35.
11. John MA, Pletch C, Hussain Z. In vitro activity of quinupristin/ dalfopristin, linezolid, telithromycin and comparator antimicrobial agents against 13 species of coagulase-negative staphylococci. J Antimicrob Chemother 2002; 50:933-38.
12. Gobernado M. Daptomicina. Un antibiótico reevaluado. Rev Esp Quimioterap 2007; 20:11-18.
13. Centres for Disease Control and Prevention. Staphylococcus aureus with reduced susceptibility to vancomycin-Illinois, 1999. MMWR 2000; 48:1165-67.
14. Hair PI, Keam SJ. Daptomicina. Revisión de su uso en el tratamiento de las infecciones complicadas de la piel y de las partes blandas y de la bacteriemia por Staphylococcus aureus. Drugs 2007; 67 (10):1483-1512.
15. Mangili A, Bica I, Snydman DR. Daptomycin-resistant, methicillin- resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2005; 40:1058-060.
16. Mensa J, Barberán J, Llinares P, Picazo JJ, Bouza E, Álvarez Lerma F, et al. Guía de tratamiento de la infección producida por Staphylococcus aureus resistente a meticilina. Rev Esp Quimioter 2008; 21:234-58.
17. Fuchs PC, Barry AL, Brown SD. In vitro antibacterial activity of daptomycin against staphylococci. J Antimicrob Chemother 2002; 49:467-70.
18. Silverman JA, Pelmutter NG, Shapiro HM. Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus. Antimicrob Agents Chemother 2003; 47:2538-44.
19. Hamilton JMT, Shah S. Activities of ciprofloxacin, levofloxacin, ofloxacin and sparfloxacin against speciated coagulase-negative staphylococci sensitive and resistant to fluorquinolones. International J Antimicrob Agents 1997; 9:127-30.
20. Rice LB, Bonomo RA. Mechanisms of resistance to antibacterial agents. In: Murray PR (Ed). Manual of Clinical Microbiology, 9th Edition 2007, P:1114-1145.